Combined Randomised and Observational Study of Type B Ankle Fracture Treatment (CROSSBAT)

June 22, 2015 updated by: Rajat Mittal, The University of New South Wales
This study will determine whether operative management confers improved short and long-term outcomes for patients with isolated AO type 44-B1 distal fibula fractures when compared with non-operative management.

Study Overview

Detailed Description

Background:

Ankle fractures are common. Recent clinical studies have shown that there is an increasing incidence of ankle fractures. Treatments vary and there is no clear consensus of the ideal approach to type 44-B1 distal fibular fractures. They range from open reduction and internal fixation to restore anatomical alignment to wearing below-knee walking plaster for an average of six weeks.

The argument for surgical fixation is that it addresses minor displacement and possible future displacement therefore potentially preventing future arthritis. On the other hand, there are numerous complications associated with surgery.

The argument for non-operative treatment is that non-union is not a common complication. Therefore surgery can be avoided in the majority of cases avoiding the clinical risks associated with surgery.

Aim:

Primary aim: To compare, ankle function and quality of life in the 12 months following an isolated AO type 44-B1 distal fibula fracture minimal talar shift, between patients treated operatively and non-operatively.

Secondary aims:

  1. To compare the recovery of ankle function and quality of life between the two study groups from 3 months to 1 year post ankle fracture
  2. To compare complications between the two groups.
  3. To conduct a health economic analysis between the two groups as indicated

Research Design: Combined Randomised and Observational Study

Methods:

Recruitment:

All consecutive patients who present to a recruiting hospital with a distal fibular fracture during the study period will be screened for eligibility. In most hospitals, all surgeons on the on-call roster will participate in the study. Consenting patients of the surgeons who have agreed to participate in the randomised arm of the trial will be invited to have their treatment randomised. Patients of surgeons involved in the observational component of the study will be invited to be included in the observational arm together with the patients who decline to be randomised, but consent to follow-up

Written, informed consent will be obtained.

Eligible patients of surgeons participating in the randomised arm will have the option of having their treatment randomised. If consent is given, the surgeon will call a central number for patient allocation that is available 24 hours per day, 7 days per week. The randomisation schedule will be prepared and administered by an external party not otherwise involved in the study. If the patient declines randomisation, treatment will be determined after surgeon-patient discussion. Eligible patients of surgeons involved in the observational arm will also have their treatment provided (operative or non-operative) as per usual surgeon practice.

Typical demographic, anthropometric and surgical details (where appropriate) will be recorded for contextual reference.

Surgical intervention:

The surgical technique for each patient managed operatively, in both the observational and randomised arms of the study, will include fixation using a plate and screws. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection, VTE and neurovascular injury. Post-operatively, all patients will be non weight bearing and placed in a below-knee plaster cast or walking boot. Discharge from hospital will be determined by the patient's ability to walk 25 m unaided by standby assistance as determined by a physiotherapist. The treating surgeon will review the patient after 10-14 days for assessment of the wound, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will then be allowed to WBAT (weight bearing as tolerated) for a further 4 weeks. This protocol represents usual post-operative practice for this injury, as determined through meetings with the Australian Orthopaedic Trauma Society.

Non-Operative management:

Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined as for the surgical arm. All patients will be reviewed between 7 and 14 days post injury with repeat radiographs by the treating surgeon. This represents usual non-operative treatment for this injury.

Other management decisions such as need for antibiotics, VTE prophylaxis or anaesthetic type will be as per usual care for that institution and recorded by the research team. Referral for further physiotherapy post removal of cast or boot (either study arm) will be based on the presence of overt ankle stiffness affecting gait. The use of physiotherapy (type and duration) will be noted. Specific prescription of the type of physiotherapy is not possible as patients will be free to access public and private services. Study participants will record all hospitalisations and visits to any health professional. They will be required to report the main reason for such health service occasions during the first year of follow-up period.

Outcomes will be collected and results will be reported in peer-reviewed journals after appropriate statistical analysis.

Study Type

Interventional

Enrollment (Actual)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia
        • Canberra Hospital
    • New South Wales
      • Brisbane, New South Wales, Australia
        • Royal Brisbane and Women's Hospital
      • Campbelltown, New South Wales, Australia, 2560
        • Campbelltown Hospital
      • Camperdown, New South Wales, Australia
        • Royal Prince Alfred
      • Caringbah, New South Wales, Australia, 2229
        • Sutherland Hospital
      • Kogarah, New South Wales, Australia, 2217
        • St. George Hospital
      • Liverpool, New South Wales, Australia, 2170
        • Liverpool Hospital
      • Melbourne, New South Wales, Australia, 3004
        • The Alfred Hospital
      • New Lambton, New South Wales, Australia, 2305
        • John Hunter Hospital
      • Parkville, New South Wales, Australia, 3050
        • The Royal Melbourne Hospital
      • Randwick, New South Wales, Australia, 2031
        • Prince of Wales Hospital
      • Westmead, New South Wales, Australia, 2145
        • Westmead Hospital
      • Wollongong, New South Wales, Australia
        • Wollongong Hospital
    • Queensland
      • Cairns, Queensland, Australia
        • Cairns Base Hospital
      • Mackay, Queensland, Australia
        • Mackay Base Hospital
      • Nambour, Queensland, Australia
        • Nambour Hospital
      • Woolloongabba, Queensland, Australia
        • Princess Alexandra Hospital
    • South Australia
      • Adelaide, South Australia, Australia
        • Royal Adelaide Hospital
      • Bedford Park, South Australia, Australia
        • Flinders Medical Centre
      • Elizabeth Vale, South Australia, Australia
        • Lyell McEwin Hospital
    • Western Australia
      • Perth, Western Australia, Australia
        • Sir Charles Gairdner Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Arbeitsgemeinschaft für Osteosynthesefragen (AO) type 44-B1 fibula fracture
  • Patients aged between 18 and 65 inclusive.
  • No talar shift - Medial clear space less than 2mm compared with the superior clear space on anterior-posterior (AP) view of the ankle.
  • Closed injury
  • No concurrent fractures/dislocations
  • Mobilising unaided/independently pre-injury
  • Willingness to be followed up for 12 months
  • Able to provide informed written consent

Exclusion Criteria:

  • Medically fit for general anaesthesia/surgery
  • Dislocation on presentation
  • Skeletally immature patients
  • Previous trauma or surgery to the affected ankle
  • Pregnancy
  • Other injuries that impede mobilisation e.g. stroke, neurovascular deficit at presentation
  • Non-English speaking

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Non-Operative
Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
ACTIVE_COMPARATOR: Operative
The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
American Academy of Orthopaedic Surgeons Foot and Ankle Questionnaire
Time Frame: 12 months
American Academy of Orthopaedic Surgeons Foot and Ankle Outcomes Questionnaire
12 months
PCS of Short Form (SF)-12v2
Time Frame: 12 months
SF-12 version 2 Health Survey
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complications
Time Frame: 6 weeks, 3, 6 and 12 months
Late surgery Infection Neurovascular complication Mortality
6 weeks, 3, 6 and 12 months
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
Time Frame: 3 and 6 months
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
3 and 6 months
MCS of Short Form (SF)-12v2
Time Frame: 3, 6 and 12 months
Short Form (SF)-12v2
3, 6 and 12 months
PCS Short Form (SF)-12v2
Time Frame: 3 and 6 months
Short Form (SF)-12v2
3 and 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Ian Harris, MBBS, PhD, FRACS, University of New South Wales, Whitlam Orthopaedic Research Centre
  • Principal Investigator: Rajat Mittal, Bsc (Med) MBBS, University of New South Wales, Whitlam Orthopaedic Research Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2010

Primary Completion (ACTUAL)

September 1, 2014

Study Completion (ACTUAL)

September 1, 2014

Study Registration Dates

First Submitted

May 28, 2010

First Submitted That Met QC Criteria

May 28, 2010

First Posted (ESTIMATE)

May 31, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

June 24, 2015

Last Update Submitted That Met QC Criteria

June 22, 2015

Last Verified

June 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CROSSBAT

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ankle Fractures

Clinical Trials on Non Operative

Subscribe